Atopic dermatitis has long been dismissed as a childhood rash, but its burden on global health rivals conditions far more recognized in public discourse — and understanding why is now reshaping how dermatology, immunology, and even psychiatry intersect. For the estimated hundreds of millions living with this condition, the past decade represents a genuine therapeutic inflection point.
This comprehensive primer in Nature Reviews Disease Primers positions atopic dermatitis as the most burdensome inflammatory skin disease by disability-adjusted life-years, ranking 15th among all non-fatal diseases globally — a statistic that reframes the condition's seriousness. The disease is driven primarily by dysregulated type 2 immune responses, which not only perpetuate skin inflammation but underpin a cascade of comorbidities including food allergy, asthma, allergic rhinitis, and eosinophilic oesophagitis. Critically, the primer documents comorbidities beyond the atopic march: mental health disorders, disrupted bone metabolism, and susceptibility to both skin and systemic infections. Adult-onset disease, particularly after age 60, is flagged as an increasingly recognized phenomenon, challenging the historical framing of atopic dermatitis as predominantly pediatric.
The mechanistic advances catalogued here — mapping interactions among the epidermal barrier, type 2 cytokine cascades, the skin microbiome, and cutaneous neural networks — have directly enabled a generation of targeted biologics (notably IL-4/IL-13 and IL-31 pathway inhibitors) and JAK inhibitors that represent a decisive departure from decades of broad corticosteroid reliance. This is confirmatory rather than paradigm-shifting territory for specialists, but the synthesis is valuable for its breadth. The most important limitation flagged is structural: global inequity in access to these advanced therapeutics means the mechanistic revolution has yet to translate into population-level relief. For health-conscious adults and clinicians alike, the takeaway is that atopic dermatitis warrants the same systemic, multi-organ clinical lens applied to metabolic or cardiovascular disease.